We're working on profiling this company soon. Let us know you're interested by sending us a request here »
We're working hard to bring you this company's profile. Register here to get an alert as soon we're done.
In the meantime, if you are interested in participating in placements on this stock click "Follow" on the toolbar above.
The ASX200 is set to open 0.44% higher today, despite weak performances on Wall Street after US Fede...
Read ArticleNeurotech appoints biotech veteran Dr Anthony Filippis as its managing director Filippis has deep u...
Read ArticleTrue to its history of reinvention and repurposing, Pharmaust will be renamed Neurizon Therapeutics...
Read ArticleMesoblast expects FDA stem cell drug approval by the first week of January ‘if not earlier’ FDA to...
Read ArticleHighlights ASX200 falls 0.67%, led by declines in mining and IT sectors. Energy sector rises, d...
Read ArticleThe ASX200 has closed 0.67% lower at 8,150 points. Investors have rising concerns about the Middl...
Read ArticleA WA listed biotech has failed in its bid to get major backing from the US Food and Drug Administrat...
Read ArticleNeurotech International (NTI) has flagged to its shareholders that the FDA hasn’t granted its produc...
Read ArticleAustralia’s clinical trials sector generated $1.6bn for the nation’s economy in 2022 according to M...
Read ArticleMTPConnect said Australia has a global reputation as a ‘go to’ destination to conduct clinical tria...
Read ArticleASX slips as US jobs data fuels Wall Street panic Westpac gets a new CEO Newcomers into the ASX...
Read ArticleNeurotech reports positive genomic analysis of NTI164 as part of Phase 1/2 PANDAS/PANS trial NTI1...
Read ArticleAdelong Gold (ASX:ADG) has engaged a new exploration consultant to advance the Adelong Gold Projec...
Read ArticleASX 200 up on Friday boosted by strong US GDP and Wall Street gains Star Entertainment gets scathin...
Read ArticleOver the last few years Neurotech International (ASX: NTI) has been gathering a significant amount o...
Read ArticleASX rises circa 0.5pc Consumer stocks in focus this week SGQ and PHX lead small caps Aussie stoc...
Read ArticleNeurotech to secure one or more strategic partnerships for NTI164 in the US, Europe and Asia Partne...
Read ArticleTryptamine’s psilocybin trial indicates potential for treating fibromyalgia Actinogen says Xanamem...
Read ArticleASX rises on Wednesday after soft June Qtr CPI bump All sectors end higher Small caps led by GTE...
Read ArticleNeurotech reports positive results from extension phase of Phase 1/2 trial of NTI164 to treat Ret...
Read ArticleThe cannabis industry is poised for growth, driven by evolving legalisation globally Investment opp...
Read ArticleThere are currently no approved treatments available to help children with Autism Spectrum Disorder...
Read ArticleASX 200 closes 0.16pc lower after modest rally from morning lows Six of 11 sectors lower, after r...
Read ArticleNeurotech reports further benefits from Phase 2/3 trial of NTI164 in autism patients Patients showe...
Read ArticleASX 200 pointing to a lower start NVDA adds another 2% as more Wall St records tumble Base metals...
Read ArticleASX 200 rises strongly on Tuesday, closes up +0.86pc All 11 sectors in the green, like Kermit on...
Read ArticleNeurotech International to establish expert PANDAS/PANS Advisory Group Advisory group follows pro...
Read ArticleAussie stocks start the week flat; energy and tech sectors lead declines Investor caution prevails...
Read ArticleNeurotech International says ASD patients in its Phase 1/2 trial of NTI164 have now been on treat...
Read ArticleAussie shares rally Rate sensitive stocks gain, led by Tech FTL soars on Newfoundland deal Aussi...
Read ArticleNeurotech reports improvements in PANDAS/PANS patients after 52 weeks of NTI164 treatment The study...
Read ArticleASX starts June positively, extending May gains Property prices in Australia rose by 0.8% in May,...
Read ArticleBell Potter says biotech very much a non-cyclical performer driven by catalysts including clinical...
Read ArticleOur biotech Investment, Neurotech International (ASX: NTI) just announced additional data from its R...
Read ArticleA listed Australian biopharmaceutical development company says it has the potential to provide the w...
Read ArticleThe ASX close higher as unemployment rate came in lower than expected Miners rally, led by BHP as...
Read ArticleWhere are we in terms of US legalisation of cannabis? What about the current legal landscape for ca...
Read ArticleThe ASX rebounded from a sluggish start… but wait, it all dipped again as we were heading out the d...
Read ArticleNeurotech’s NTIRTT1 becomes first clinical trial to show statistically significant clinical improve...
Read ArticleToday, our biotech Investment Neurotech International (ASX: NTI) announced that BOTH of its clinical...
Read ArticleNeurotech International (ASX:NTI), has attained a new milestone in its clinical trial for Autism Spe...
Read ArticleClinical-stage biopharmaceutical development company Neurotech International (ASX: NTI) has confirme...
Read ArticleAussie shares set to rise again after a modest tick up on Wall Street Gold price hit a new high...
Read ArticleBlinkLab is a world-first, AI-driven digital healthcare venture, that uses a smartphone and facial r...
Read ArticleWe are Invested in Neurotech International (ASX: NTI) - a clinical stage biotech company.
Read ArticleMorgans says more money could flow into ASX healthcare sector in 2024 as higher interest rate cycle...
Read ArticleNeurotech International (ASX:NTI) has announced the extension of its Phase 1/2 clinical tria...
Read ArticleLocal markets give up early gains then regains them, closing 0.22pc higher Consumer Discretionary...
Read Article12-week Phase I/II clinical trial to treat Rett Syndrome with NTI164 broad spectrum cannabinoid dru...
Read ArticleBiopharmaceutical development company Neurotech International (ASX: NTI) has extended a Phase I/II c...
Read ArticleMike Tyson has spoken out against the jailing of cannabis users Iron Mike owns his own cannabis bra...
Read ArticleASX200 drops about 0.7pc on Wednesday Consumer Staples craters, as WOW CEO departs Small Caps led...
Read ArticleNeurotech International (ASX: NTI) has announced “highly significant” improvements during the extens...
Read ArticleBiotech doesn’t need another pandemic for a resurgence – it’s made a strong comeback regardless. Sto...
Read ArticleNeurotech International (ASX: NTI) is currently running a Phase I/II clinical trial for Rett Syndrom...
Read ArticleImmuron reports record sales for Travelan in January Neurotech extends Phase 1/2 clinical trial for...
Read ArticleClinical-stage biopharmaceutical development company Neurotech International (ASX: NTI) has received...
Read ArticleASX to rise as Dow Jones hits fresh record Chipmaker Arm rises by almost 30pc Bitcoin has topped...
Read ArticleClinical-stage biopharmaceutical development company Neurotech International (ASX: NTI) has updated...
Read ArticleNeurotech says due to often negative publicity around cannabis companies it tends not to promote it...
Read ArticleClinical-stage biopharmaceutical development company Neurotech International (ASX: NTI) has been rec...
Read ArticleNeurotech has a clear path for development and commercialisation of NTI164 to treat PANDAS/PANS W...
Read ArticleNeurotech International (ASX: NTI) continues to make excellent progress in accelerating its speciali...
Read ArticlePaediatric patients with PANDAS/PANS treated with Neurotech’s NTI164 showed marked improvements Anx...
Read ArticleStockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might h...
Read ArticlePaediatric neurological disorders specialist Neurotech International (ASX: NTI) has received promisi...
Read ArticleBenchmark index falls to 11-month lows Utilities only sector in green Small caps led by Noxopharm...
Read ArticleClinical-stage biopharmaceutical company Neurotech International (ASX: NTI) has completed the recrui...
Read ArticleCannabis stocks are rebounding, catching short sellers off guard Next signpost for weed investors i...
Read Article2023 a case of “haves and have nots” for ASX biotech sector as companies with good catalysts lead t...
Read ArticleStockhead’s Top 10 at shortly-before-11-ish, published once our panel of the world’s best chocolatie...
Read ArticleSeveral ASX companies are undergoing rigorous clinical trials to gain regulatory approval for their...
Read ArticleA unique Australian trial currently being conducted by Neurotech International (ASX: NTI) is looking...
Read ArticleThe FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergenc...
Read ArticleStockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might h...
Read ArticleCannabis stocks jumped after marijuana rescheduling recommendation in the US Study in Australia sho...
Read ArticleStockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might h...
Read ArticleBiopharmaceutical development company Neurotech International (ASX: NTI) has achieved a last patient...
Read ArticleFutures point to the ASX opening fairly flat this morning on another busy day of reporting. Today...
Read ArticleMoneyTalks is Stockhead’s regular recap of the ASX stocks, sectors and trends that fund managers and...
Read ArticleThe end of pandemic and higher rates have subdued biotech market But there are signs now the sector...
Read ArticleClinical-stage biopharmaceutical development company Neurotech International (ASX: NTI) has reached...
Read ArticleThe ASX 200 had a positive finish to the day on the whole, on the back of the rates pause from the...
Read ArticleThis content is created by Smallcaps Authors. [Author : Imelda Cotton] Clinical-stage biopharmaceu...
Read ArticleClinical-stage biopharmaceutical development company Neurotech International (ASX: NTI) has updated...
Read ArticleNeurotech is following in the footsteps of 2023 market darling of the ASX biotech sector Neuren with...
Read ArticleSocial media platforms are rushing to update their advertising policies on cannabis Meta was the mo...
Read ArticleWith the Human Research Ethics Committee (HREC) approval and Clinical Trial Notification (CTN) schem...
Read ArticleThis content is created by Smallcaps Authors. [Author : Colin Hay] Specialist biopharmaceutical de...
Read ArticleBod Science provided a ‘landmark update’ on its Phase IIB insomnia clinical trial Neurotech receive...
Read ArticleZelira announced that its diabetic nerve pain drug outperforms Pfizer’s Lyrica Diabetes is a huge m...
Read ArticleThe weed industry has slumped as it faces several headwinds But new data suggests the industry will...
Read ArticleThis content is created by Smallcaps Authors. [Author : Imelda Cotton] The Human Research Ethics C...
Read ArticleNeurotech will extend its Phase 1/2 trial after ethics approval Alcidion makes further inroads into...
Read ArticleThis content is created by Smallcaps Authors. [Author : Imelda Cotton] Clinical-stage biopharmaceu...
Read ArticleStudies confirm that cannabis relieves pain in cancer patients In addition, cannabis also improves...
Read ArticleThis content is created by Smallcaps Authors. [Author : Lorna Nicholas] Neurotech International (A...
Read ArticleThis content is created by Smallcaps Authors. [Author : Lorna Nicholas] Clinical stage biopharmace...
Read ArticleChemist Warehouse joins WNX JV to develop new cannabis products Neurotech launches new clinical pro...
Read ArticleHealius gets takeover offer from ALC, a company more than half its size Neurotech will launch Phase...
Read ArticleThis content is created by Smallcaps Authors. [Author : Imelda Cotton] Clinical-stage biopharmaceu...
Read ArticleThis content is created by Smallcaps Authors. [Author : Filip Karinja] Emerging drug developer Neu...
Read ArticleNeurotech (ASX:NTI) has today announced the final clinical results from its 11 paediatric Autism Spe...
Read ArticleThe ASX bounced back from the week’s drama to close up by 0.86% The XEC Emerging Companies Index cl...
Read ArticleThis content is created by Smallcaps Authors. [Author : Filip Karinja] Emerging drug developer Neu...
Read ArticleTwitter to allow cannabis companies to advertise in US states where it’s legal Elixnol comes out on...
Read ArticleNeurotech International (NTI) treats its first patient in its phase one and two paediatric clinical...
Read ArticleNeurotech International (NTI) is granted approval to begin phase one and two paediatric clinical tri...
Read ArticleUS States who allow recreational cannabis see less codeine demand WA GP wants Snoop Dogg to drop in...
Read ArticleGood gravy, what a Monday that was – the Stockhead newsroom’s been busier than Santa’s elves this we...
Read ArticleUBI will have its work published on the front cover of respected publication Neurotech gets green l...
Read ArticleNeurotech International (NTI) taps investors for $9 million to fund its paediatric clinical trials p...
Read ArticleGermany looks to legalise recreational cannabis and US and Canadian companies are paying attention ...
Read ArticleNeurotech says its NTI164 drug for paediatric autism showed improvements in symptoms Arovella closi...
Read ArticleASX200 is in the green on Wednesday morning New British PM brings yields back to Pre-Liz levels Ama...
Read ArticleTuesday. The day when the grind of the week is well and truly entrenched, and the weekend is just a...
Read ArticleThe ASX 200 trims gains to end circa 0.3% higher Small caps drop 0.2%, but C29 Metals booms China m...
Read ArticlePatrys crosses blood brain barrier in health animals Cynata receives Notice of Acceptance from IP A...
Read ArticleNeurotech is anticipating results from its extended world first study of a medicinal cannabis produc...
Read ArticleCambridge says cannabis smokers are not actually lazy, that’s a myth USyd wants to test home-grown...
Read ArticleNeurotech International has made key appointments and changes to its board as it focuses on its deve...
Read ArticleIt’s quarterlies season as the ASX market announcements page becomes increasingly flooded with lodge...
Read ArticleThe recent trial results success could pave the way to test other neurological illnesses, as well as...
Read ArticleNeurotech International (NTI) reports 93 per cent of patients showed symptom improvements in a rece...
Read ArticleMGC Pharma to go Phase 2 on COVID-19 in South Africa Neurotech says cannabis strain works well in c...
Read ArticleNeurotech has released promising results from a world first study of a medicinal cannabis product in...
Read ArticleThe ASX 200 and XEC small cap indices rise Attention turns to Tuesday’s date with RBA destiny Celsi...
Read ArticleA medical dilemma in its own right – the modern treatment of the condition commonly known as ‘autism...
Read ArticleA Thai university says adding cannabis to chicken feed has positive results on meat and egg quality...
Read ArticleNeurotech International (ASX:NTI) has reported positive preclinical research demonstrating t...
Read ArticleNeurotech International’s (NTI) preclinical research demonstrates its proprietary cannabis strain c...
Read ArticleNeurotech says its cannabis strain NTI164 demonstrates strong results when combined with Diclofenac...
Read ArticleShareCafeWebinar Recap – NTI, MHK, RPM & ESK Catch up on the full webinar with presentations fr...
Read ArticleShareCafeNeurotech International (ASX: NTI) – Webinar Presentation Dr. Alexandra Andrews – CEO – Ne...
Read ArticleActor Woody Harrelson has opened a cannabis store in West Hollywood Releaf has plans for a weed wel...
Read ArticleKiwi medical device company TruScreen (ASX:TRU) surged 15% this morning after releasing the results...
Read ArticleV-Con is Stockhead’s investing focused video conference series, bringing you expert insights, panel...
Read ArticleNeurotech International (NTI) appoints Alexandra Andrews as Chief Executive Officer (CEO), effectiv...
Read ArticleThe ASX 200 Health Index (XHJ) is trading lower by 0.30% at the time of writing, compared to the bro...
Read ArticleNeurotech International (ASX:NTI) says preclinical studies demonstrate that NTI164 can impro...
Read ArticleThe ASX 200 was unable to break free from its recent shackles, edging lower by 0.11% in the Wednesda...
Read ArticleMinerals260 (ASX:MI6), a spinoff from Liontown Resources (ASX:LTR), enjoyed a positive debut despite...
Read ArticleShareCafeHidden Gems Webinar Recap – NAOS Asset Management, MMM, NTI & ACW Catch up on the ful...
Read ArticleResults demonstrated the ability of Neurotech’s NTI/Dolce strains to suppress COX-2 – the main enzym...
Read ArticleThe results give NTI further momentum as it pursues an expanded development pathway for its propriet...
Read ArticleNeurotech International Limited (ASX:NTI) has announced the continuation of its pre-clinical program...
Read ArticleNeurotech International (ASX:NTI) has announced that Professor Allan Cripps AO has been appo...
Read ArticleThe federal government’s “patent box” initiative caught the eye of Australia’s biotech sector in Tue...
Read ArticleNeurotech International (ASX:NTI) has announced the commencement of a phase 1/2 open-label c...
Read ArticleSummary Neurotech International has commenced Phase I/II open-label clinical trial in children h...
Read ArticleNeurotech International Limited (ASX:NTI) has commenced a Phase I/II open label clinical study in 20...
Read ArticleThe company’s preparations over the last quarter means that it is now ready to conduct Phase I and I...
Read ArticleThe capital raisings boom on the ASX is continuing in 2021 with nearly $10 billion raised in the fir...
Read ArticleASX pot stocks have run hot in recent months but eight in particular have been particularly rewardin...
Read ArticleAustralia’s medical marijuana industry is showing strong growth, according to an industry-leading bi...
Read ArticleNeurotech International Limited (ASX:NTI) has announced a strategic cultivation partnership with Can...
Read ArticleNeurotech International Limited (ASX:NTI) has expanded its exclusive license with Dolce Cann Global...
Read ArticleNeurotech International Limited (ASX:NTI) has provided an update on its clinical study program. As w...
Read ArticleNeurotech International Limited (ASX:NTI) has provided a comprehensive overview and update regarding...
Read ArticleNeurotech International Ltd (ASX:NTI) has today confirmed the successful completion of in-vitro stud...
Read Article–The below is a company sponsored announcement– ASX cannabis stocks are gaining momentum, stimulat...
Read ArticleThe last month has been an extremely rewarding period for Neurotech International Limited (ASX:NTI)...
Read ArticleSpecial Report: Neurotech International (ASX:NTI) says laboratory tests have confirmed the neuro-pro...
Read ArticleShareCafeHidden Gems Webinar Recap – NTI, RLG, 3DP, EMV Catch up on the full webinar with presentat...
Read ArticleShareCafeNeurotech International (ASX: NTI) – Hidden Gems Webinar Presentation Presenter – Brian Le...
Read ArticleSpecial Report: Neurotech International (ASX:NTI) has a new chairman and a new focus – cannabis trea...
Read ArticleSpecial Report: Austism treatment specialist Neurotech International says unique strains of cannabis...
Read ArticleA quick wrap of the ASX’s key winners and losers on Friday, August 21. Data is taken after the marke...
Read ArticleA quick wrap of the ASX’s key winners and losers on Tuesday, August 18. Data is taken after the mark...
Read ArticleA quick wrap of the ASX’s key winners and losers on Wednesday, July 22. Data is taken after the mark...
Read ArticleA quick wrap of the ASX’s key winners and losers on Tuesday, July 21. Data is taken after the market...
Read ArticleA quick wrap of the key winners and losers on Monday, July 6. Data is taken after the market closes...
Read ArticleNeurotech International (ASX: NTI) has collared an exclusive global licence to use Dolce Cann Global...
Read ArticleA quick wrap of the key winners and losers on Wednesday, June 24. Data is taken after the market clo...
Read ArticleA quick wrap of the key winners and losers on Friday, June 19. Data is taken after the market closes...
Read ArticleHere’s our fortnightly wrap of all the news driving ASX health stocks. Of the ASX’s 134-odd small ca...
Read ArticleA quick wrap of the key winners and losers on Tuesday, June 9. Data is taken after the market closes...
Read ArticleStockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade....
Read ArticleBackpackers in Bondi were pilloried for spreading COVID-19, but everyone knows gonorrhoea is a great...
Read ArticleWith the health and life science sector being the ASX’s top performer last year, Western Australia i...
Read ArticleThe ASX had its worst day of the year so far as it woke up from Australia Day weekend to find global...
Read ArticleAutism treatment company Neurotech International (NTI) has had its flagship device cancelled from t...
Read ArticleAntisense Therapeutics (ASX:ANP) jumped over 20 per cent this morning on news its ATL1102 drug, figh...
Read ArticleStockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade....
Read ArticleStockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade....
Read ArticleIn 2019, 10 stocks have gained more than 200 per cent in a single day. Stockhead recaps these stocks...
Read ArticleAt Stockhead we are as amazed as our readers when stocks rise by over 100 per cent in a day. But its...
Read ArticleLeading medical device company Neurotech International (ASX:NTI) this week reported highly promising...
Read Article
Open an account with an online broker of your choice. If you do not have an existing broker, consider Vested Equities' A$9.50 flat fee platform.
Sign up now »Place your order however you wish. If you need advice on buying or selling, you should seek the assistance of a full service financial adviser experienced in small cap equities.
